Australia's largest stock trading and investment forum Australia's #1 stock forum

AHI

Click for more information

0.00%

9.2¢ advanced health intelligence ltd

Ann: Tinjoy WinScan Launch and Preregistration Update, page-30

First 30 Last

Share
Profile

Follow
thewood

164 Posts.

74

31/07/21

12:09

Post #: 54926594
Share

Originally posted by powersweep ↑

"the wood" I am lost with the terminology and question re "subset", however thinking the objective is to see whether AHI attains their full financial entitlements from the pre-registrations, i provide the following input.
Copy and paste of part of the announcement:
"The initial preregistration launch only offered annual subscription of 310 Chinese Yuan (AUD$64.86). Under the 12-month subscription, subscribers have unlimited Body Scans and 52 Face Scans. Under the terms of the preregistration, the party must register with their We-Chat payment gateway. With a total initial preregistration number of 114,391 users, Tinjoy have achieved an initial revenue commitment from its users of 35,461,210 Chinese Yuan (AUD$7,417,637)."
"Importantly, investors should be aware as previously announced, the agreement with Tinjoy is a gross revenue share arrangement with a 70/30 split. With AHI receiving 70% of the revenue. There are no deductions from the revenue generated”

Noting as pre-registration requires provision of credit card details for the annual subscription, and based on the numbers who have pre-registered in just three (3) days alone provides AHI with: $5,192,345 AUD ($432,695 AUD per month).

Expand

Thank you Powersweep I appreciate your reply

AHI Price at posting: $1.09 Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 12 more messages in this thread...

First 30 Last

Add AHI (ASX) to my watchlist